Complicated Peptic Ulcer with CC DRG

DRG 381 addresses complicated peptic ulcer disease with a Complication or Comorbidity, encompassing conditions such as bleeding, perforation, or obstruction that require inpatient management. This classification matters for inpatient reimbursement because documented complications influence the Diagnosis-Related Group assignment and thus the Medicare payment level for the admission.

DRG 381 Overview

DRG 381 covers inpatient admissions for complicated peptic ulcer disease with a documented Complication or Comorbidity. This category includes ulcers with bleeding, perforation, obstruction, or other inpatient complications that increase resource use. It is important for Medicare payment because the presence of a Complication or Comorbidity adjusts reimbursement relative to uncomplicated ulcer cases. Accurate clinical coding and documentation determine whether a case is classified to this Diagnosis-Related Group for payment purposes.

Acute hemostasis and endoscopic intervention studies: randomized or controlled studies that evaluate timing, techniques, or adjunctive measures for achieving hemostasis during hospitalization for bleeding or perforated peptic ulcers. These trials enroll adults admitted with complicated peptic ulcer disease who require urgent endoscopy, angiographic embolization, or surgical intervention, and compare outcomes such as rebleeding rates, transfusion needs, need for emergency surgery, length of stay, and in-hospital mortality. Results inform procedural best practices and resource use during the acute inpatient episode, which directly affects provider decision-making and short-term reimbursement and utilization for this DRG.
Comparative effectiveness studies of medical management strategies during the index admission: pragmatic trials or cohort studies comparing different inpatient pharmacologic regimens (for example, acid suppression strategies, H. pylori testing-and-eradication protocols, or transfusion thresholds) and standardized care pathways for patients with complicated ulcers and comorbidities. These studies target heterogeneous hospitalized populations including elderly patients, those on antiplatelet/anticoagulant therapy, and patients with renal or cardiopulmonary disease to determine which approaches reduce complications, readmissions, and downstream procedures. Findings are relevant to payers and hospital administrators because optimized in-hospital medical management can lower complication rates and downstream costs while impacting DRG case-mix and penalties related to readmissions or prolonged stays.
Post-discharge outcomes and care-transition studies: longitudinal observational cohorts and interventional trials that assess readmission risk reduction, outpatient follow-up strategies, medication adherence, and secondary prevention (including H. pylori eradication verification) after discharge for complicated peptic ulcer. These studies focus on the transition from inpatient to outpatient care in patients who survived an index complicated ulcer admission, often emphasizing high-risk subgroups such as older adults, those with substance use, or patients on chronic antithrombotic therapy. Results guide care coordination programs and value-based payment models because reducing 30-day readmissions and complications after discharge has direct implications for both quality metrics and overall cost-of-care related to this DRG.

Acute hemostasis and endoscopic intervention studies: randomized or controlled studies that evaluate timing, techniques, or adjunctive measures for achieving hemostasis during hospitalization for bleeding or perforated peptic ulcers. These trials enroll adults admitted with complicated peptic ulcer disease who require urgent endoscopy, angiographic embolization, or surgical intervention, and compare outcomes such as rebleeding rates, transfusion needs, need for emergency surgery, length of stay, and in-hospital mortality. Results inform procedural best practices and resource use during the acute inpatient episode, which directly affects provider decision-making and short-term reimbursement and utilization for this DRG.
Comparative effectiveness studies of medical management strategies during the index admission: pragmatic trials or cohort studies comparing different inpatient pharmacologic regimens (for example, acid suppression strategies, H. pylori testing-and-eradication protocols, or transfusion thresholds) and standardized care pathways for patients with complicated ulcers and comorbidities. These studies target heterogeneous hospitalized populations including elderly patients, those on antiplatelet/anticoagulant therapy, and patients with renal or cardiopulmonary disease to determine which approaches reduce complications, readmissions, and downstream procedures. Findings are relevant to payers and hospital administrators because optimized in-hospital medical management can lower complication rates and downstream costs while impacting DRG case-mix and penalties related to readmissions or prolonged stays.
Post-discharge outcomes and care-transition studies: longitudinal observational cohorts and interventional trials that assess readmission risk reduction, outpatient follow-up strategies, medication adherence, and secondary prevention (including H. pylori eradication verification) after discharge for complicated peptic ulcer. These studies focus on the transition from inpatient to outpatient care in patients who survived an index complicated ulcer admission, often emphasizing high-risk subgroups such as older adults, those with substance use, or patients on chronic antithrombotic therapy. Results guide care coordination programs and value-based payment models because reducing 30-day readmissions and complications after discharge has direct implications for both quality metrics and overall cost-of-care related to this DRG.

OpenPayer

Summary & Overview

Complicated Peptic Ulcer with CC: Inpatient Reimbursement Overview

DRG 381 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes